These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20978365)

  • 1. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.
    Jang HW; Choi JY; Lee JI; Kim HK; Shin HW; Shin JH; Kim SW; Chung JH
    Endocr J; 2010; 57(12):1045-54. PubMed ID: 20978365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
    Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
    Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F-18 FDG PET detection of a medullary thyroid carcinoma in a patient with metastatic colonic cancer; literature review.
    Cohen R; Bihan H; des Guetz G; Wind P; Martin A
    Ann Endocrinol (Paris); 2009 Dec; 70(6):468-72. PubMed ID: 19744643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
    Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
    Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.
    Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D
    Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
    de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
    Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ¹⁸F-FDG-PET and ¹⁸F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis.
    Cheng X; Bao L; Xu Z; Li D; Wang J; Li Y
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):136-42. PubMed ID: 22498184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
    J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.